|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,476,663: Dexmedetomidine Hydrochloride Compositions and Methods
U.S. Patent 5,476,663, titled "Dexmedetomidine hydrochloride compositions and methods," was granted on December 19, 1995. The patent covers specific compositions of dexmedetomidine hydrochloride and methods of using these compositions. Dexmedetomidine is a potent alpha-2 adrenergic agonist used as a sedative and analgesic. This analysis examines the patent's scope, claims, and its position within the broader drug patent landscape.
What is the core invention claimed in U.S. Patent 5,476,663?
The patent claims compositions and methods related to dexmedetomidine hydrochloride. Specifically, it focuses on pharmaceutical compositions containing dexmedetomidine hydrochloride in a specific concentration range, suitable for parenteral administration. The methods described pertain to the use of these compositions for sedation and analgesia in humans and animals.
The key elements protected by the patent include:
- Pharmaceutical Compositions: These compositions are defined by the presence of dexmedetomidine hydrochloride. The claims specify that the concentration of dexmedetomidine hydrochloride in these compositions should be within a particular range, typically expressed as a percentage by weight or volume. This specificity is crucial for defining the boundaries of the protected invention.
- Parenteral Administration: The patent explicitly addresses administration routes that bypass the digestive tract, such as intravenous or intramuscular injection. This indicates a focus on formulations designed for rapid systemic delivery.
- Therapeutic Use: The claimed methods relate to the therapeutic applications of these compositions. This includes the use of dexmedetomidine hydrochloride for inducing and maintaining sedation, as well as for providing analgesia. The patent may also cover specific patient populations or clinical scenarios where these uses are particularly advantageous.
What are the specific claims made in the patent?
U.S. Patent 5,476,663 contains several independent and dependent claims that define the scope of the invention. While the exact wording of all claims requires a detailed review of the patent document, the core claims typically address:
- Claim 1 (Example of an independent claim): A pharmaceutical composition comprising dexmedetomidine hydrochloride in a concentration of approximately 0.001% to 0.1% by weight, and a pharmaceutically acceptable carrier, adapted for parenteral administration.
- Claim 2 (Example of a dependent claim building on Claim 1): The composition of claim 1, wherein the concentration of dexmedetomidine hydrochloride is approximately 0.004% by weight.
- Claim 3 (Example of a method claim): A method of sedating a human or animal patient, comprising parenterally administering to the patient a pharmaceutical composition comprising dexmedetomidine hydrochloride in a concentration of approximately 0.001% to 0.1% by weight.
- Claim 4 (Example of a method claim with specific indication): The method of claim 3, wherein the patient is undergoing a surgical procedure.
The claims are structured to provide broad protection for the core invention while allowing for specific variations and applications through dependent claims. The concentration range is a critical defining feature, distinguishing the patented composition from other potential formulations of dexmedetomidine. The patent's claims are the legal basis for its protection and are crucial for understanding its market exclusivity.
What is the patent landscape for dexmedetomidine?
The patent landscape for dexmedetomidine is characterized by a series of patents covering its synthesis, formulations, and various therapeutic applications. U.S. Patent 5,476,663 is one of many patents that have contributed to the commercial development and market exclusivity of dexmedetomidine-based products.
Key aspects of the dexmedetomidine patent landscape include:
- Original Composition of Matter Patents: The initial patents for dexmedetomidine itself would have covered the molecule and its fundamental properties. These are typically the earliest and broadest patents in a drug's lifecycle.
- Formulation Patents: Patents like U.S. Patent 5,476,663 protect specific formulations designed for optimal delivery, stability, and efficacy. These patents can extend market exclusivity beyond the expiration of the original composition of matter patents. For dexmedetomidine, these formulations are often optimized for intravenous infusion, such as the specific concentrations mentioned in the patent.
- Method of Use Patents: These patents claim novel therapeutic uses or specific patient populations for which the drug is effective. This can include indications like sedation in intensive care units (ICUs), procedural sedation, or analgesia.
- Manufacturing Process Patents: Patents may also cover improved or novel methods of synthesizing dexmedetomidine, which can offer a competitive advantage.
Comparison with Other Sedatives:
The patent landscape for dexmedetomidine can be understood in comparison to other sedatives. For instance, propofol, another widely used intravenous anesthetic and sedative, has its own complex patent history. Propofol's initial patents have long expired, but subsequent patents have focused on novel formulations, delivery systems, and methods of use, such as preventing propofol infusion syndrome or specific patient monitoring techniques.
The patent strategy for dexmedetomidine, including patents like 5,476,663, reflects a common pharmaceutical approach: securing intellectual property protection not only for the active pharmaceutical ingredient (API) but also for the specific ways in which it is formulated and administered to achieve particular therapeutic outcomes. This multi-layered patenting strategy is designed to maximize the period of market exclusivity.
What is the expiration date of U.S. Patent 5,476,663?
U.S. Patent 5,476,663 was granted on December 19, 1995. Under standard U.S. patent law at the time of its grant, the patent term was 17 years from the date of grant.
Therefore, the expiration date of U.S. Patent 5,476,663 is December 19, 2012.
It is important to note that patent terms can be extended under certain circumstances, such as through the Patent Term Adjustment (PTA) or Patent Term Extension (PTE) provisions of the U.S. patent law. PTE is typically available for pharmaceutical patents to compensate for regulatory review delays. However, without specific documentation indicating a PTE or PTA for this particular patent, the standard term of 17 years from the grant date is applied.
What are the implications of this patent for generic competition?
The expiration of U.S. Patent 5,476,663 on December 19, 2012, has significant implications for generic competition for dexmedetomidine hydrochloride products.
Key implications include:
- Loss of Exclusivity: Upon patent expiration, the market exclusivity granted by this specific patent is lost. This allows other pharmaceutical companies to seek approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to market generic versions of dexmedetomidine hydrochloride.
- Entry of Generic Products: Following the expiration of key patents, generic manufacturers can file Abbreviated New Drug Applications (ANDAs) with the FDA. An ANDA requires demonstrating that the generic product is bioequivalent to the branded reference product and meets all quality standards.
- Price Reduction: The introduction of generic alternatives typically leads to a substantial decrease in the price of the drug. This is a direct result of increased competition among multiple manufacturers. Branded drugs often maintain premium pricing during their patent-protected periods, but this advantage diminishes significantly with generic entry.
- Market Share Shift: Over time, generic products tend to capture a significant portion of the market share previously held by the branded product. This shift is driven by cost savings for healthcare providers, pharmacies, and patients.
- Continued Patent Protection for Other Aspects: While U.S. Patent 5,476,663 has expired, it is possible that other patents related to dexmedetomidine, such as those covering different formulations, manufacturing processes, or specific methods of use, may still be in effect. The existence of these other patents can influence the timing and extent of generic competition. For example, a patent on a specific sustained-release formulation would not prevent the launch of a generic version of the immediate-release formulation protected by 5,476,663.
The expiration of this patent marks a critical juncture for the commercial lifecycle of dexmedetomidine hydrochloride, paving the way for wider accessibility and potentially lower healthcare costs associated with its use.
How does this patent relate to the development of Precedex®?
Precedex® is the brand name for dexmedetomidine hydrochloride manufactured by Hospira (now part of Pfizer). The development and commercialization of Precedex® are directly linked to the patent protection surrounding dexmedetomidine, including patents like U.S. Patent 5,476,663.
The relationship can be understood as follows:
- Foundation for Commercialization: U.S. Patent 5,476,663, which claims specific pharmaceutical compositions of dexmedetomidine hydrochloride suitable for parenteral administration and their therapeutic uses, would have been instrumental in securing market exclusivity for the early formulations of dexmedetomidine. This exclusivity is essential for a pharmaceutical company to recoup its significant investment in research, development, and clinical trials.
- Target Formulation: The claims in patent 5,476,663 likely describe the specific concentration and formulation characteristics of the initial dexmedetomidine product brought to market, such as Precedex®. The patent provided the legal basis to prevent competitors from marketing identical or highly similar products during its term.
- Market Exclusivity Period: The term of patent 5,476,663, expiring in 2012, defined a period during which Hospira (and its predecessors) could market Precedex® without direct generic competition for the protected formulation. This allowed for a period of premium pricing and market establishment.
- Post-Patent Expiration Landscape: With the expiration of this patent, the market for dexmedetomidine hydrochloride opened up to generic manufacturers. This has led to the introduction of generic versions of Precedex®, increasing competition and driving down prices. However, it is possible that other patents may still provide some level of protection for specific aspects of dexmedetomidine's use or formulation, influencing the competitive landscape for newer or specialized applications.
In essence, U.S. Patent 5,476,663 was a critical piece of intellectual property that supported the initial market entry and protection of dexmedetomidine hydrochloride products like Precedex®. Its expiration is a predictable event that shifts the market dynamics from a monopolistic to a competitive environment.
Key Takeaways
- U.S. Patent 5,476,663, granted in 1995, protects specific pharmaceutical compositions of dexmedetomidine hydrochloride and methods of their parenteral administration for sedation and analgesia.
- The patent claims focus on defined concentration ranges of dexmedetomidine hydrochloride in parenteral formulations.
- The patent expired on December 19, 2012, ending its period of market exclusivity for the protected compositions and methods.
- The expiration of this patent opened the door for generic manufacturers to enter the market, leading to increased competition and price reductions for dexmedetomidine hydrochloride products.
- This patent played a crucial role in the early commercialization and market protection of dexmedetomidine hydrochloride products, such as Precedex®.
- While this patent has expired, the broader patent landscape for dexmedetomidine may include other active patents covering different formulations, uses, or manufacturing processes.
Frequently Asked Questions
-
What was the primary therapeutic area targeted by the claims in U.S. Patent 5,476,663?
The primary therapeutic areas targeted were sedation and analgesia, particularly for patients requiring parenteral administration.
-
Does the expiration of U.S. Patent 5,476,663 mean all dexmedetomidine products are now available as generics?
No. While this patent's expiration allows for generic versions of the specific compositions and methods it claimed, other dexmedetomidine products might be protected by different, subsequently granted patents covering alternative formulations, routes of administration, or specific therapeutic indications.
-
Can a company manufacture dexmedetomidine hydrochloride if U.S. Patent 5,476,663 has expired, but they are not using the specific concentration range claimed?
A company can manufacture dexmedetomidine hydrochloride if they are not infringing any other currently valid patents and their product does not fall within the scope of expired claims from patents like 5,476,663. However, they would still need to adhere to all regulatory requirements for drug approval.
-
What is the significance of the "parenteral administration" aspect in the patent claims?
"Parenteral administration" signifies that the patent is focused on delivery methods that bypass the gastrointestinal tract, such as intravenous or intramuscular injection. This is crucial for drugs intended for rapid onset of action or for patients unable to take oral medications, and it differentiates the patented formulations from oral dosage forms.
-
How does U.S. Patent 5,476,663 contribute to the overall patent life of a drug like dexmedetomidine?
This type of patent contributes by extending the period of market exclusivity beyond the initial composition-of-matter patents. Formulation patents and method-of-use patents can provide protection for new and improved ways of delivering or using a drug, thereby prolonging the innovator’s ability to control the market.
Citations
[1] U.S. Patent 5,476,663. (1995). Dexmedetomidine hydrochloride compositions and methods. Retrieved from the United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
